Related Experiment Video
Updated: Jun 28, 2026
Tumor Hypoxia Assessment: In Vivo 3D Oxygen Imaging Through Electron Paramagnetic Resonance
Published on: February 14, 2025
Imaging of tumor hypoxia to predict treatment sensitivity
H Minn1, T J Grönroos, G Komar
1Turku PET Centre and Department of Oncology and Radiotherapy, University of Turku, PO BOX 52, FI-20520 Turku, Finland. heikki.minn@utu.fi
Abstract:
Non-invasive detection of tumor hypoxia using radiolabeled 2-nitroimidazoles has been a major effort during the last two decades. Recent years have witnessed the introduction of several new compounds which are chemically related to [(18)F]fluoromisonidazole (FMISO) but show slight but distinct differences in biodistribution and metabolic clearance. Although [(18)F]FMISO has shown clinical potential it suffers from suboptimal oxygen dependent tissue contrast and newer agents seek to improve this essential feature. The limited data on other interesting tracers keeps the investigators busy at demonstrating the potential advantages over [(18)F]FMISO while efforts should start to concentrate on proving the clinical significance of such techniques in the form of outcome data from image-guided therapy modification. We review here our experiences with two hypoxia-avid agents [(18)F]fluoroerythronitromidazole (FETNIM) and [(18)F] 2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide (EF5) and focus on the similarities and differences of these two tracers in comparison to other radiolabeled 2-nitroimidazoles. It is recognized that only [(18)F]FMISO has thus far shown clinical utility and newer tracers need to be tested against this circumstance.
Insights
New radiolabeled 2-nitroimidazoles aim to improve tumor hypoxia detection beyond [(18)F]fluoromisonidazole (FMISO). While promising, newer agents like FETNIM and EF5 require clinical outcome data to prove their significance.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiochemistry
Background:
- Non-invasive tumor hypoxia detection is crucial for cancer treatment.
- Radiolabeled 2-nitroimidazoles are key imaging agents.
- [(18)F]fluoromisonidazole (FMISO) is a clinically used tracer but has limitations.
Purpose of the Study:
- To review experiences with [(18)F]fluoroerythronitromidazole (FETNIM) and [(18)F] 2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide (EF5).
- To compare FETNIM and EF5 with other radiolabeled 2-nitroimidazoles, focusing on differences and similarities.
- To emphasize the need for clinical significance and outcome data for novel hypoxia imaging agents.
Main Methods:
- Review of existing literature and investigator experiences.
- Comparative analysis of biodistribution and metabolic clearance of different tracers.
- Focus on hypoxia-avid agents, including FETNIM and EF5.
Main Results:
- Newer agents show distinct biodistribution and clearance compared to FMISO.
- These agents aim to improve oxygen-dependent tissue contrast.
- Limited clinical data exists for newer tracers compared to FMISO.
Conclusions:
- [(18)F]FMISO remains the only clinically utilized hypoxia tracer.
- Novel tracers like FETNIM and EF5 require rigorous clinical validation.
- Future efforts must focus on demonstrating clinical utility and outcome benefits through image-guided therapy.
